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ABSTRACT
Urofacial syndrome (UFS) is an autosomal recessive congenital disease featuringgrimacing
and incomplete bladder emptying. Mutations of HPSE2, encoding heparanase 2, a
heparanase 1 inhibitor, occur in UFS, but knowledge about theHPSE2mutation spec-
trum is limited. Here, seven UFS kindreds with HPSE2 mutations are presented,
including one with deleted asparagine 254, suggesting a role for this amino acid,
which is conserved in vertebrate orthologs.HPSE2mutations were absent in 23 non-
neurogenic neurogenic bladder probands and, of 439 families with nonsyndromic
vesicoureteric reﬂux, only one carried a putative pathogenic HPSE2 variant. Homo-
zygousHpse2mutantmouse bladders contained urinemore often than didwild-type
organs, phenocopying human UFS. Pelvic ganglia neural cell bodies contained
heparanase 1, heparanase 2, and leucine-rich repeats and immunoglobulin-like
domains-2 (LRIG2), which is mutated in certain UFS families. In conclusion, hepara-
nase 2 is an autonomic neural protein implicated in bladder emptying, but HPSE2
variants are uncommon in urinary diseases resembling UFS.
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Urofacial, or Ochoa, syndrome (UFS) is
an autosomal recessive congenital dis-
ease.1–7 Affected children have enuresis
and incomplete bladder emptying asso-
ciated with detrusor and bladder outlet
dyssynergic contractions. ESRD, uro-
sepsis and vesicoureteric reﬂux (VUR)
can occur. UFS individuals have ab-
normal facial movements when crying
and smiling. Biallelic mutations of
HPSE2 cause UFS.4–7 HPSE2 encodes
heparanase 2,8 which inhibits endo-b-D-
glucuronidase activity of heparanase 1,9
itself implicated in releasing growth
factors from heparan sulfate proteogly-
cans.10–12
Since the ﬁrst descriptions ofHPSE2
mutations inUFS in 2010,4,5 only two fur-
ther such families have been reported.6,7
We here describe seven newUFS kindreds
withHPSE2mutations, representing the
largest series to date of genetically de-
ﬁned, overtly unrelated families. Their
mutations and key clinical features are
listed in Table 1. The Supplemental
Material details their clinical histories
and investigations, and Supplemental
Figure 1 illustrates examples of facial
grimacing and dysmorphic bladders.
Considering these and previously pub-
lishedmutations4–7 (Figure 1A), it is clear
that pathogenic HPSE2 mutations are
found across the gene’s coding region.
Most (i.e., nonsense or frameshift muta-
tions) would cause loss of function, but a
subset may generate abnormal proteins.
In Family 2, the deleted amino acids in
exon 3 correspond to the linker sequence
in heparanase 1 cleaved to yield an active
enzyme,8–11 and an exon 3 deletion was
previously reported in a Spanish child
with UFS.4 The in-frame deletion of as-
paragine 254 in Family 6 targets an amino
acid conserved between human, mouse,
and frog heparanase 2.12 It is predicted
to be nitrogen-linked glycosylated13 (Fig-
ure 1A) and may direct endoplasmic
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reticulum processing of heparanase 2.13
Mahmood et al.7 reported a homozy-
gous HPSE2 mutation changing aspara-
gine 543 to isoleucine. The asparagine,
located in the carboxy-terminus, is also
highly conserved between vertebrate
orthologs,12 but it is not predicted to
be glycosylated. Its role needs further
study.
Certain HPSE2 mutations found
in apparently unrelated UFS families
might be explained by founder effects
(e.g., c.1465_1466del AA [p.Asn489-
Profs*126] in Irish kindreds).5 In this
study, the c.457C.T (p.Arg153*) muta-
tion was found in Families 2, 4, and 7
from Portugal, Turkey, and Kosovo, re-
spectively, and was reported in Turkish
UFS twins.4 Despite sharing a mutation
(c.1516C.T, p. Arg506*),5 disease se-
verity varied in Ochoa’s Columbian
UFS cohort2 and some individuals were
recognized as having UFS only after the
syndrome was diagnosed in a relative. In
this report, probands in Families 4 and 5
were part of the pediatric cohort 4C
Study, all with renal insufﬁciency and a
subset with urinary tract anomalies. In
both families, the UFS diagnosis had not
been considered before our genetic
screen and, moreover, UFS in siblings
was recognized only after diagnosis of
the syndrome in probands. Thus, UFS
is probably underrecognized, particu-
larly when urinary tract features are
mild. Such phenotypic variability may
be due to environmental inﬂuences (e.g.,
superimposedurosepsis) or geneticmod-
iﬁers. Mutations of LRIG2, encoding
leucine-rich repeats and immunoglobulin-
likedomains 2, exist in someUFS families
lackingHPSE2mutations.14We excluded
the possibility (data not shown) that pro-
bands in Families 4 and 5, who had severe
kidney disease, also carried mutations of
LRIG2.
Compound heterozygous missense
LRIG2 variants have been reported14 in
1 of 23 individuals with non-neurogenic
neurogenic bladder, which phenocop-
ies15 the UFS bladder. Moreover, pri-
mary nonsyndromic VUR is heritable
in humans,16,17 so perhaps primary
VUR is associated with rare variants in
genes such as HPSE2 . HPSE2 was
sequenced and multiplex ligation-
dependent probe ampliﬁcation under-
taken in 23 non-neurogenic neurogenic
bladder individuals.14 No mutations
were detected. HPSE2 was sequenced in
probands from 193 United Kingdom
and 246 Irish families with nonsyn-
dromic VUR.16,17 In one, a heterozygous
novel variant (c.422_423insGCCCGG-
p.Asp141delinsGluProGly
[NM_021828.4]) was detected; he pre-
sented neonatally with urosepsis and
unilateral VUR. A sister with unilateral
VUR carried one copy of the variant, an
in-frame deletion of Asp141 with inser-
tion of three residues, GluProGly (Figure
1, B and C). The insertion lies between
the equivalent sequence, which links the
two heparanase 1 subunits,8,9 and thus,
by analogy, may functionally disrupt
heparanase 2. Heterozygous missense
variants with a minor allele frequency
,1% (Supplemental Table 1) were not
over-represented in patients (5 of 439
probands) versus European ancestry
controls (38 of 6503 cases; P=0.2).
It has been speculated that UFS blad-
der defects are neurogenic because sim-
ilar dyssynergia can occur after spinal
cord damage.2,18 Moreover, nerves in-
vading human fetal bladders contain
heparanase 2 and LRIG2.14 At mouse
embryonic days (E) 14 and 17 (Supple-
mental Figure 2 and data not shown),
Hpse2 transcripts were detected by RT-
PCR in the bladder, metanephros, hind-
gut, neural tube, and eye. Lrig2 RNAwas
detected in these locations and in the
brain, heart, and liver. Pelvic ganglia give
rise to postganglionic parasympathetic
axons mediating detrusor contraction,
while lumbar ganglia emit postganglionic
sympathetic axons mediating detrusor re-
laxation and sphincter contraction.19,20
Immunohistochemistry at E14 (Figure
2A) showed heparanase 2 in pelvic and
lumbar ganglia; nerves running in blad-
der wall mesenchyme, beginning to form
smoothmuscle at this stage21; mesenchy-
mal ureteric cells; and peripheral nerves
within the head. The protein data accord
with Hpse2 transcripts being detectable
in embryonic pelvic ganglia,22 where
Hpse2+ cells coexpress SRY-related
HMG-box 10, which regulates neural crest
development.19 LRIG2 and heparanase 1
were also immunodetected in E14 pelvic
and lumbar ganglia. Postnatally, bladder
wall nerves and pelvic ganglia contained
heparanase 1 and 2 and LRIG2 (Figure 2,
B–I). Heparanase 1 elicits neuritogenesis
in cell culture,23 and heparanase 2 inhibits
its enzymatic activity.13 Thus, the HPSE2
gene product may modify heparanase 1
activity within ganglia. Our observation
that LRIG2 was also present in pelvic gan-
glia, combined with a report that LRIG2
modiﬁes growth factor signaling in gli-
oma cells,24 suggests that LRIG2 may
operate in similar biologic pathways as
heparanase 2. If autonomic nerve function
is perturbed, then the cyclic low-pressure
storage of urine and complete bladder
emptying will be impaired.20We speculate
that this abnormal scenario operates in
UFS. Here, there is an analogy with an-
other congenital bladder disease inwhich
M3, the cholinergic receptor mediating
detrusor contraction, is mutated.25
Mating heterozygous mice carrying a
gene trap in intron 6 ofHpse2 led to birth
of wild-type, heterozygous, and homo-
zygous offspring in Mendelian ratios.
Homozygous mutant tissue contained a
truncated Hpse2 transcript but lacked
wild-type Hpse2 transcripts extending
beyond the trap (Figure 3A). Given that
UFS is a congenital disease characterized
by incomplete bladder emptying, we
studied bladders in the ﬁrst month of
life when neural circuits normally be-
come established.26 At autopsy, we re-
corded whether bladders appeared as
“full” translucent globes or “empty”
opaque beads (Figure 3B). In the ﬁrst
fortnight after birth (Figure 3C), of 17
wild-type bladders, 4 were full and 13
empty; of 14 homozygous bladders, 13
were full and 1 empty (wild-type versus
mutant; P,0.001, Fisher exact test, two
tailed). In the second fortnight, all 15
wild-type bladders were empty; of 29
homozygous bladders, 14 were full and
15 were empty (P50.001). Heterozy-
gous bladders did not differ signiﬁcantly
from wild-types, and there was no in-
ﬂuence of sex. Injecting India ink into
homozygous bladders demonstrated ure-
thral patency. In humans with UFS,
large bladders have been reported
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antenatally and neonatally,3 whereas
bladder capacity may be normal later
in childhood (e.g., Family 3). Perhaps
the change in bladder phenotype be-
tween the ﬁrst and second postnatal
fortnights inHpse2mutantmice (93%ver-
sus 48% “full”) reﬂects an analogous evo-
lution of dysfunction in this species.
Homozygous mutant bladders con-
tained muscle and urothelium (Figure 3,
D and J). Quantitative PCR showed sim-
ilar levels of epithelial (uroplakin 3A)
and smooth muscle (a-smooth muscle
actin and myosin heavy chain 11) tran-
scripts in homozygous and wild-type lit-
termate bladders harvested at 1 and 14
days after birth (Supplemental Figure 3).
These results argue against a primary
myogenic defect, as is present in the pre-
viously reported megabladder mutant
mouse.27 In turn, this supports the con-
clusion that the HPSE2 gene product is
necessary for peripheral neural control
of bladder function. Heparanase 2 deﬁ-
ciency during Xenopus embryogenesis
increases phospho-ERK (pERK),12 so
we immunoprobedmouse pelvic ganglia
for pERK (Supplemental Figure 4).
Although a subset of neural cell bodies
immunostained for pERK, the patterns
were similar in mutants and wild-type
littermates. So, if heparanase 2 acts to
modulate intracellular signaling in pel-
vic ganglia, it may do so by other means,
and we note that the heparanase 1, itself
antagonized by heparanase 2,13 regulates
AKTand SRC as well as ERK signaling.10
Homozygous mice showed poor
weight gain in the third week, and sub-
sequently some died. We performed
autopsies in postnatal weeks 2–3. No
pathologic abnormality was noted in
the lungs. Homozygous kidneys were
grossly normal, with a well deﬁned cor-
tex, outer medulla. and papilla (compare
Figure 3, E–H, with Figure 3, K–N).
These ﬁndings accord with the observa-
tion12 that knockdown of heparanase 2
in embryonic frogs does not lead to
overtly malformed pronephric kidneys.
Although Hpse2 mutant mouse kidneys
lacked major aplastic/hypodysplastic
malformations, three harbored focal
cortical defects manifest as glomerular
crowding (compare Figure 3, H and N)
and/or tubular atrophy (compare Figure
3, I and O). Whether these are analogous
to isotope scanning defects detected in
some UFS kidneys (e.g., Families 3–5),
and which may result from ascending
infection, remains to be established.
CONCISE METHODS
Human Genetic Studies
Since discovering mutations of HPSE24 and
LRIG214 mutations in UFS, our research lab-
oratory has sought mutations of these genes
in other UFS families. Ethical approval was
granted, and informed consent was obtained
from all patients and/or their parents. Paren-
tal consent was obtained to show images of
faces. Human studies were approved by in-
stitutional ethical review and approval (Uni-
versity of Manchester [06138] and National
Health Service ethics committees [06/Q1406/
52 and 11/NW/0021]). The VUR DNA sam-
ples from the United Kingdomwere collected
under National Research Ethics Service no.
MREC/01/6/15. Irish VUR DNA samples
were collected at Our Lady’s Children’s Hos-
pital Crumlin and the National Children’s
Hospital, Tallaght, Dublin, Ireland. HPSE24
and LRIG214 were sequenced as previously
described. Multiplex ligation-dependent
probe ampliﬁcation was carried out using
MRC-Holland reagents and standard proto-
col with custom made probes (conditions
available on request).
Splicing Experiment
In silico prediction performed using the Hu-
man Splice Finder (www.umd.be/HSF) pre-
dicted that c.1099–1G.A mutates the splice
acceptor of exon 8 and that potential alterna-
tive splice acceptor sites exist at nucleotides
c.1100 and c.1121 within exon 8. HPSE2 is
not expressed by lymphocytes, so we were
unable to prove the alternate splicing by se-
quencing of constitutional cDNA. To assess
effects of the missense mutation on splicing,
we therefore performed a splicing assay using
the pTB vector28 to express mini-gene con-
structs of the mutated and wild-type HSPE2
sequence in HEK293 cells. Brieﬂy, exon 8 and
approximately 500 bp of ﬂanking sequence
Figure 1. HPSE2 mutations in UFS and the variant in primary VUR. (A) Schematic of
heparanase 2 showing location of mutations. Dark blue indicates mutations described in
this report. Light blue indicates mutations from previous reports. Blue stars, nonsense or
frameshift mutations; circle, missense mutation; diamond, splice-site mutation; red stars,
predicted N-glycosylation sites; #, founder mutation in Ochoa’s Columbian cohort. Do-
mains were predicted by Pfam and SignalP. N and C, the proteins amino and carboxy
terminals, respectively. (B and C) Wild-type full length wild-type heparanase 2 protein (B)
and the c.422_423insGCCCGG-p.Asp141delinsGluProGly variant (C). The heparanase 2
sequence was aligned to 51 a-L-arabinofuranosidase with ClustalW, and the structural
model was generated using PHYRE2 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?
id=index).
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AAGCAC39 containing appended NdeI re-
striction sites. Amplicons derived from patient
and control DNA were cloned into TOPO
pCR2.1 vector and, following veriﬁcation of
correct sequence (BigDye Terminator v3.1Cycle
Sequencing Kit, analyzed on the Applied Bio-
systems 3730xl DNA analyzer), were subse-
quently subcloned asNdeI digested fragments
into the pTB vector using standard proce-
dures. DNA of the mutant and wild-type
expression constructs was prepared from bac-
terial cultures using the Qiagenmini-prep kit.
For analysis of splicing, HEK293 cells cul-
tured in low glucose DMEM (Invitrogen)
supplemented with 10% FBS and 1% penicil-
lin were transfected with the pTB mini-gene
constructs using Effectene transfection re-
agents (Qiagen) according to themanufactur-
er’s protocol. RNA was extracted 24 hours
after transfection using theRNeasy kit (Qiagen)
according to the manufacturer’s protocol.
cDNAwas synthesized using sequence speciﬁc
oligo primers (59TGTGCCTCCAGCTG-
AGGTGGT39, internal exon 8 sequence and
59GGTCACCAGGAAGTTGGTTAAATCA39,
pTB vector speciﬁc sequence) with Promega
reverse transcription reagents according
to a standard protocol. PCR ampliﬁcation
was performed using forward primer
59CAACTTCAAGCTCCTAAGCCACTGC39-
with reverse primers 59TGTGCCTCCAG-
CTGAGGTGGT39 and 59GGTCACCAGGA-
AGTTGGTTAAATCA39.
PCR products were puriﬁed by gel extrac-
tion (EMD Millipore Montage DNA gel
extraction kit) and sequenced as previously
described. Two predominant variants were
produced by expression of the mutant allele.
The 59 pTB exon was spliced into two alter-
nate splice acceptors within exon 8,
NM_021828.4 c.1100 and c.1121 (as predic-
ted by Human Splice Finder). These both re-
sult in a frameshift that would be predicted
to result in a premature stop mutation and
nonsense mediated decay (p.Val367Glyfs*2
or p.Val367Lysfs*6).
Immunohistochemistry
Tissues were ﬁxed in 4% paraformaldehyde
and embedded in parafﬁn. Sections of 5 mm
were mounted on polylysine-coated glass
Figure 2. Immunohistochemistry in wild-type mice detects UFS proteins. Sections were
counterstained (blue) with hematoxylin. Positive immunodetection signals are brown. (A)
Embryonic day 14. Note the similar patterns for heparanase 2 and LRIG2 in a bladder wall
nerve, a nascent pelvic ganglion, a nascent lumber ganglion,mesenchymal-like cells in the
wall of the proximal (i.e., top of the) ureter, and the lingual nerve. Heparanase 1 was also
detected in the ganglia cell bodies but not in the nerve trunks themselves. (B–D) Serial
sections of 1-week postnatal bladder immunostained for heparanase 2 (B) or LRIG2 (C). (D)
The primary antibody was omitted. Note signals for both proteins in the nerve (running
from top right to bottom left). (E–I) Immunohistochemistry of pelvic ganglia ﬂanking the
bladder outﬂow tract 2 weeks after birth: b3-tubulin, a neuronal marker (E); heparanase 2
(F); heparanase 1 (G); LRIG2 (H); negative control with no primary antibody (I). Scale bars
are 50 mm.
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slides. Endogenous peroxidase was quenched
by incubation with hydrogen peroxide (30%
solution in PBS). Antigen exposure was under-
taken by heating at 95°C for 5 minutes in so-
dium citrate (pH, 6). Antibodies were used at
optimized concentrations in PBS Triton-X
(0.1%). Primary antibodies used were against
b3-tubulin (AB9354; EMD Millipore),
heparanase 1 (OBT1975G; AbD Serotec),
heparanase 2 generated against NH2-
QLDPSIIHDGWLDC-CONH2 (Generon) as
validated by Roberts et al.,17 LRIG2 (AP13821b;
Abgent), and pERK (Sigma-Aldrich). Each was
mixed with 3% serum speciﬁc to the species
of the secondary antibody and incubated
overnight at 4°C. Secondary antibodies
were added for 2 hours at 4°C, followed by
streptavidin-horseradish peroxidase (Vector)
for 1 hour. 3, 3’-diaminobenzidine (Vector)
was added for 2 minutes, and sections were
counterstainedwith hematoxylin and/or eosin.
For immunoﬂuorescence, Alexa Fluor second-
ary antibodies (Life Technologies)were applied
for 1 hour at room temperature, washed in
PBS, and incubated with DAPI (Vector) for
10 minutes, washed in PBS, and mounted
with Mowiol; a coverslip was then applied
and sealed with nail varnish.
Detection of Hpse2 and Lrig2
Transcripts in Wild-Type Mice
Total RNAwas extracted and following Dnase1
treatment, cDNA was generated by standard
techniques. PCR was performed using Reddy
Mix(ThermoFisherScientiﬁc)andthefollowing
primers: Hpse2 forward 59CTTAAGCTCCAA-




and Gapdh forward 59GGGTTCCTATAAA-
TACGGACTGC39 and reverse 59 CCATTT-
TGTCTACGGGACGA39.
Mutant Mice
Mouse experiments were ethically approved by
the University of Manchester Biologic Services
Facility committee and the UK Home Ofﬁce
(PPL 40/3550, Modeling human UT malfor-
mations). Hpse2 gene trap mice were initially
studied on amixed (129SvEvBrd3C57BL6N)
background; subsequent experiments showed
a similar bladder phenotype on a C3H back-
ground. Mutant founders were generated at
the Texas A&M Institute of Genetic Medicine
from embryonic stem cells infected with a
replication-defective retrovirus (http://www.tigm.
org/). The gene trap vector VICTR4829 was
found to have inserted into the sixth intron
of Hpse2, which is located on chromosome
19 (Mouse accession NM_001081257 and
Omnibank clone OST441123). The gene trap
is predicted to cause splicing of exon 6 ofHpse2
with inclusion of aNeo cassette and premature
stop codon. Genotyping was carried out
using a common forward primer (59C-
CAGCCCTAATGCAATTACC39) and wild-
type (59TGAGCACTCACTTAAAAGGAC39)
or gene trap (59ATAAACCCTCTTGCAG-
TTGCA39) reverse primers. RT-PCRswere un-
dertaken to detect wild-type and gene trap in-
sertion transcripts in postnatal bladders using
the primers: Hpse2 exon 5 forward
59CGGACGGCCCAGGAAGAACG39; Hpse2
exon 9 reverse 59TCCGTGGTCGAAAA-
ATGAATGTC39; and Neo reverse r59TG-
TGCCCAGTCATAGCCGAATAGC39. Samples
were run on a 1% agarose gel with SafeView
nucleic acid stain (NBS Biologic). After weaning,
Figure 3. Hpse2mutant mouse bladder and kidney phenotypes. (A) RT-PCR of RNA from
postnatal bladders. Note the abnormal Hpse2 transcript (N, 158 base pairs) in gene trap
homozygous (Hom) and heterozygous (Het) tissues. Thewild-typeHpse2 transcript (W, 364
base pairs) was the only one present in wild-type (Wt) mice but was not detected in ho-
mozygous (Hom) tissue. The right side of the gel shows the experiment when RT was not
used. (B) Examples of “full” and “empty” bladder phenotypes in autopsies of mice in the
ﬁrst and second postnatal fortnights. (C) Frequencies of “full” bladder phenotypes in the
three genotypes, in the ﬁrst and second postnatal fortnights (total numbers analyzed are
also shown). (D–O) Histology of mutant mouse bladders and kidneys; D–I are wild-type
organs and J–O are homozygous mutant organs. All sections were stained with hema-
toxylin; I andOwere also stainedwith eosin. Wild-type (D) and homozygousHpse2mutant
(J) bladders at 2 weeks. Notemuscle in walls of both organs. When bladders are harvested,
urine can escape and organs tend to deﬂate. Nevertheless, an impression of the difference
between homozygous andwild-type bladders is shown in the low power insets (upper right
of each frame). Wild-type kidneys at 2 weeks showing sagittal section overview (E) and
higher powers of papilla (F), medullary tubules (G), and glomeruli (H). Counterpart zones in
littermate homozygous kidney (K–N) are grossly similar to those in wild-type organ. An area
of glomerular crowding in amutant kidney is shown inN (from areamarked by asterisk in K).
High-power views of outer cortex in 3-week-old kidneys from wild-type (I) and mutant (O)
littermate mice. Note the small area (demarcated by arrowheads in O) of glomerular
crowding and tubulo-interstitial changes next to a concavity (asterisk) in the organ’s sur-
face. Scale bars are 50 mm.
802 Journal of the American Society of Nephrology J Am Soc Nephrol 26: 797–804, 2015
BRIEF COMMUNICATION www.jasn.org
homozygous mutant mice fail to gain weight
and die when maintained for more than 1
month of age. The cause of their death is un-
known. By contrast, heterozygous mice ap-
pear healthy; they are fertile and live to over
15 months of age. For quantitative PCR on
mutant bladders, reactions were performed
on a StepOnePlus platform (Applied Biosys-
tems) and data analyzed using the accompa-
nying software. The following Taqman probes
(Applied Biosystems) were used: Hprt1, used
as a reference housekeeping transcript
(Mm00446968_m1); Acta2 (Mm00656102_m1);
Myh11 (Mm00443013_m1); and Upk3a:
(Mm00452321_m1).
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